United States tariffs on medicines have threatened global drug supply chains, says an association representing Swiss pharmaceutical companies. +Get the most important news from Switzerland in your inbox Customs barriers disrupt production and supply chains and hinder research and development, Interpharma told AWP. They also threaten to permanently damage the close and important economic cooperation between Switzerland and the US. + How pharma became Switzerland’s Achilles heel in the US The association hopes bilateral talks can continue to either reduce or exempt tariffs on drugs. However, the announcement is a "wake-up call", says Interpharma. Trump's plan hits Switzerland's most important export sector, which is crucial not only for prosperity, but also for tax revenues and research. In 2024 alone, the branch exported medicines worth more than CHF100 billion. + Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs The association urged ...
